anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the first postoperative days following minimally invasive sacroiliac joint fusion (MISJF), patients often report serious pain, which contributes to high utilization of painkillers and prevention of early mobilization. This prospective, double-blind randomized controlled trial investigates the effectiveness of intraoperative SIJ infiltration with bupivacaine 0.50% versus placebo (NaCl 0.9%) in 42 patients in reducing postoperative pain after MISJF. The primary outcome was difference in pain between bupivacaine and placebo groups, assessed as fixed factor in a linear mixed model. Secondary outcomes were opioid consumption, patient satisfaction, adverse events, and length of hospital stay. We found that SIJ infiltration with bupivacaine did not affect postoperative pain scores in comparison with placebo, neither as group-effect (p = 0.68), nor dependent on time (group*time: p = 0.87). None of the secondary outcome parameters were affected in the postoperative period in comparison with placebo, including opioid consumption (p = 0.81). To conclude, intra-articular infiltration of the SIJ with bupivacaine at the end of MISJF surgery is not effective in reducing postoperative pain. Hence, we do not recommend routine use of intraoperative SIJ infiltration with analgesia in MISJF.
Provided are an emulsion composition, a cosmetic composition, and a method for preparing an emulsion composition, in which the oil components are not limited to vegetable oils, and which do not require xanthan gum or welan gum as an essential component.  The emulsion composition contains an oil component, an aqueous dispersion medium, an emulsifier, and CNF.  The CNF is an emulsion stabilizer, and obtained by unmodified cellulose defibration, and the emulsifier amount is less than 20 mass% of the total composition.  The cosmetic composition contains the emulsion composition.  The method includes preparing an oil phase, preparing an aqueous phase, and emulsifying by mixing the oil and aqueous phases.  CNF obtained by defibrating unmodified cellulose is added in at least preparing an aqueous phase or emulsifying, and an emulsifier is added in at least preparing an oil phase, preparing an aqueous phase, or emulsifying.
Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
The invention discloses a traditional Chinese medicine composition for treating a bone disease. The traditional Chinese medicine composition comprises the following components according to the weight unit of 20-30g of saffron crocus, 50-60g of lucid ganoderma, 10-20g of nux vomica, 30-40g of root of bidentate achyranthes, 20-30g of radix rubiae, 50-60g of herba pyrolae, 30-40g of herba epimedii, 50-60g of lycopodium clavatum, 20-30g of liquorice, 20-30g of garden balsam stem, 10-20g of radix sophorae flavescentis, 60-70g of silky ant, and 5000-6000g of ginger. The traditional Chinese medicine composition is externally used, and can be used for suffocating, dipping, smearing and scrubbing. Each component can be directly smeared and treated on the full body after being crushed, and then coated by a preservative film after being smeared. The traditional Chinese medicine composition has the effects of promoting blood circulation and regulating qi, strengthening tendons and bones, dissipating blood stasis and activating blood circulation, clearing and activating the channels and collaterals, eliminating stagnation and dredging blood stasis, is free of damage to a human body, free of pain, wide in medicinal herb source, and free of toxic and side effects, and can effectively treat the bone disease. 122 sufferers in all are treated, the effective rate is 93.6% and the good rate is 89.4%.
Cochlear spiral ganglion neurons (SGNs) are bipolar ganglion cells and are the first neurons in the auditory transduction pathway. They transmit complex acoustic information from hair cells to second-order sensory neurons in the cochlear nucleus for sound processing. Injury to SGNs causes largely irreversible hearing impairment because these neurons are highly differentiated cells and cannot regenerate, making treatment of sensorineural hearing loss (SNHL) arising from SGN injury difficult. When exposed to ototoxic drugs or damaging levels of noise or when there is loss of neurotrophic factors (NTFs), aging, and presence of other factors, SGNs can be irreversibly damaged, resulting in SNHL. It has been found that NTFs and stem cells can induce regeneration among dead spiral ganglion cells. In this paper, we summarized the present knowledge regarding injury, protection, and regeneration of SGNs.
Hair composition comprising: a) a hydroxypropyl guar hydroxypropyltrimonium chloride having an average molecular weight ranging from about 2,000,000 g.mol-1 to about 3,500,000 g/mol (e.g. at 0.001 to 5.0 wt.%); and b) at least one divalent or trivalent metal salt (e.g. at 0.005 to 10 weight per cent). The metal salt may be an organic or inorganic salt of copper, zinc, iron, calcium, magnesium, lanthanum (III) or aluminium. Preferably, the metal salt is chloride or lactate, potentially lanthanum chloride or magnesium chloride. The composition may be a shampoo or hair conditioner and may further comprise a surfactant. Also claimed is a method of reducing colour washout from chemically dyed hair comprising applying to the hair a composition defined herein. Further claimed is the use of a composition described herein to reduce colour washout from chemically-dyed hair.
BACKGROUND: The 3-variable number-of-risk-factors (NRF) model is a prognostic tool for patients undergoing palliative radiotherapy (PRT). However, there is little research on the NRF model for patients with painful non-bone-metastasis tumours treated with PRT, and the efficacy of the NRF model in predicting survival is unclear to date. Therefore, we aimed to assess the prognostic accuracy of a 3-variable NRF model in patients undergoing PRT for bone and non- bone-metastasis tumours.
METHODS: This was a secondary analysis of studies on PRT for bone-metastasis (BM) and PRT for miscellaneous painful tumours (MPTs), including non-BM tumours. Patients were grouped in the NRF model and survival was compared between groups. Discrimination was evaluated using a time-independent C-index and a time-dependent area under the receiver operating characteristic curve (AUROC). A calibration curve was used to assess the agreement between predicted and observed survival.
RESULTS: We analysed 485 patients in the BM group and 302 patients in the MPT group. The median survival times in the BM group for groups I, II, and III were 35.1, 10.1, and 3.3 months, respectively (P < 0.001), while in the MPT group, they were 22.1, 9.5, and 4.6 months, respectively (P < 0.001). The C-index was 0.689 in the BM group and 0.625 in the MPT group. In the BM group, time-dependent AUROCs over 2 to 24 months ranged from 0.738 to 0.765, while in the MPT group, they ranged from 0.650 to 0.689, with both groups showing consistent accuracy over time. The calibration curve showed a reasonable agreement between the predicted and observed survival.
CONCLUSIONS: The NRF model predicted survival moderately well in both the BM and MPT groups.
PURPOSE:To prepare the title powder excellent in the adsorption capacity, etc., and useful for an external skin preparation, deodorant, etc., by coating the surfaces of particles of a powder with a powder contg. magnesium aluminosilicate as te essential component. CONSTITUTION:A powder selected from the group consisting of nylon 6, polyethylene, polystyrene, polytetrafluoroethylene, aluminum sulfate, etc., is prepd. in advance. The surfaces of particles of the powder are coated with a powder of magnesium aluminosilicate or a mixture thereof with at least one other powder (e.g. bentonite) to give the title powder. An example of the method for carrying out the coating is ball mill mixing. The coated powder is excellent in the adsorption capacity of skin egesta such as lower fatty acids and lipid peroxide, water absorbing and releasing properties, deodorizing effect, etc.
The purpose of this study is to characterize tinnitus and PTSD symptomatically, neurobiologically, and causally, applying causal modeling to psychometric and neurofunctional data. We will enroll 30 individuals with both tinnitus and PTSD. Participants will be asked to complete baseline assessments of subjective tinnitus distress, PTSD, depression, and resting-state fMRI at baseline. Individuals with comorbid tinnitus and PTSD who are eligible for the study will receive 12 sessions of Cognitive Processing Therapy (CPT) over a 6- to 15-week period. CPT is a trauma-focused treatment for PTSD that guides individuals on how to recognize and challenge thoughts that are erroneous and dysfunctional. One-month follow-up assessments of tinnitus-related distress, PTSD, depression, and anxiety will be conducted, along with resting-state functional magnetic resonance imaging (fMRI).
Humans exhibit considerable variability in their immune responses to the same immune challenges. Such variation is widespread and affects individual and population-level susceptibility to infectious diseases and immune disorders. Although the factors influencing immune response diversity are partially understood, what mechanisms lead to the wide range of immune traits in healthy individuals remain largely unexplained. Here, we discuss the role that natural selection has played in driving phenotypic differences in immune responses across populations and present-day susceptibility to immune-related disorders. Further, we touch on future directions in the field of immunogenomics, highlighting the value of expanding this work to human populations globally, the utility of modeling the immune response as a dynamic process, and the importance of considering the potential polygenic nature of natural selection. Identifying loci acted upon by evolution may further pinpoint variants critically involved in disease etiology, and designing studies to capture these effects will enrich our understanding of the genetic contributions to immunity and immune dysregulation.
The present invention relates to batroxobin, named as Haemocoagulase Acutus, Halase for short, which is separated and purified from Agkistrodon acutus enzymes. The present invention also relates to an application of Haemocoagulase Acutus for preparing medicines for treating hemorrhagic disease. The Haemocoagulase Acutus is glucoprotein composed of two subunits connected by disulfide bonds. The measurement results of 15 amino acid sequences at a terminal N are as follows: a subunit A: DCPSDWSSYEGHCYK, a subunit B: DCSSGWSSYEGHCYK. The molecular weight of the present invention is 29076.1Da, the isoelectric point is 5.78, and the present invention contains 1.89% to 1.95% of neutral hexose. When the Haemocoagulase Acutus is used for preparing a preparation for injection, a raw medicine of Agkistrodon acutus and an excipient of dextran are dissolved with water for injection, the volume is metered to a certain value, and then, the solution is filtered, sterilized, separately filled, frozen and dried to obtain Haemocoagulase Acutus sterile injection powder for injection. The preparation is white freeze-drying powder, has no smell and no taste and is easy to dissolve in water, and the water solution is clear and transparent. Pharmacological experiments and toxicological experiments indicate that the product has strong hemostatic effects and has low toxicity, the Haemocoagulase Acutus is a new hemostatic medicine which has similar hemostatic effects with reptilase but has a totally different structure.
Disclosed is a curable composition which is chemically polymerizable, which can achieve extremely high adhesion strength even when not being irradiated with light, and which is intended to be used in the dental field. Specifically disclosed is a curable composition for dental applications, which comprises (A) a polymerizable monomeric component comprising an acidic monomer, (B) water, and (C) a chemical polymerization initiator component comprising a radical-generating species and a reactive species capable of generating a radical upon being reacted with the radical-generating species. The curable composition is stored in the form divided into two or more packages. The polymerization/curing of the curable composition can be achieved by mixing the components packed in the packages with each other. One package (I) among the packages includes the components (A) and (B), and contains a polyvalent metal ion in an mount of 0.3 to 10 meq relative to 1 gram of the polymerizable monomeric component (A) included in the package (I). The chemical polymerization initiator (C) is stored in the form divided into at least two packages so as to prevent the contact between the radical-producing species and the reactive species.
The twin pairs discordant for incident type 2 diabetes (iT2D) \[17 monozygotic (MZ) and 20 dizygotic twin pairs (DZ)\] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iT2D while his co-twin did not or develop iT2D at least one year later.
The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention. Also disclosed are methods of using the disclosed immunogens, for example to protect individuals from RSV infection. Also disclosed are methods of using the disclosed antibody proteins, for example to protect individuals from RSV infection.
INTRODUCTION: We showed in a phase II randomised controlled trial (RCT) that oral sildenafil citrate in term labour halved operative birth for fetal distress. We outline the protocol for a phase III RCT (can intrapartum SildEnafil safely Avert the Risks of Contraction-induced Hypoxia? (iSEARCH)) of 3200 women in Australia to assess if sildenafil citrate reduces adverse perinatal outcomes related to intrapartum hypoxia.
METHODS AND ANALYSIS: iSEARCH will enrol 3200 Australian women in term labour to determine whether up to three 50 mg oral doses of sildenafil citrate versus placebo reduce the relative risk of a primary composite end point of 10 perinatal outcomes potentially related to intrapartum hypoxia by 35% (from 7% to 4.55%). Secondary aims are to evaluate reductions in the relative risk of emergency caesarean section or instrumental vaginal birth for fetal distress by 25% (from 20% to 15%) and in healthcare costs. To detect a 35% reduction in the primary outcome for an alpha of 0.05 and power of 80% with 10% dropout in each arm requires 3200 women (1600 in each arm). This sample size will also yield >90% power to detect a 25% reduction for the secondary outcome of any operative birth (caesarean section or instrumental vaginal birth) for fetal distress.
ETHICS AND DISSEMINATION: Ethical approval for the iSEARCH RCT was granted by the Hunter New England Human Research Ethics Committee (ref no: 2020/ETH02791). Results will be disseminated through websites, peer-reviewed publications, scientific meetings and social media, news outlets, television and radio.
TRIAL REGISTRATION NUMBER: ACTRN12621000231842.
The present invention relates to an injection igecycline combination and the preparing method. The combination comprises igecycline and antioxidant. The weight percentage of igecycline is 10 and the weight percentage of antioxidant is 0.01 to 10. The combination can also comprise 0 weight percent to 200 weight percent of excipient or 0 weight percent to 1 weight percent of chelating agent. Firstly excipient, antioxidant and chelating agent are weighed and taken according to a recipe quantity, and then injection water is added for melting. Igecycline is added according to the recipe quantity. Injection water is added to total content and is stirred to melt. The pH value is regulated between 7.0 and 9.0. Then 0.5 g per liter to 2 g per liter of medical solution bulk of needle carbon is added and is stirred at room temperature and is filtrated to eliminate carbon. A filtrate is rough filtrated and fine filtrated to remove bacteria. Content of the fine filtrated solution is mensurated and loading quantity is calculated according to labeled amount. Split charging, refrigeration and drying, vacuum capping and gland, the injection igecycline combination obtained. The injection igecycline combination is stable in quality, free of pollution, easy in operation storage and transport.
BACKGROUND: Although chronic erosive gastritis (CEG) is common, its clinical characteristics have not been fully elucidated. The lack of consensus regarding its treatment has resulted in varied treatment regimens.
AIM: To explore the clinical characteristics, treatment patterns, and short-term outcomes in CEG patients in China.
METHODS: We recruited patients with chronic non-atrophic or mild-to-moderate atrophic gastritis with erosion based on endoscopy and pathology. Patients and treating physicians completed a questionnaire regarding history, endoscopic findings, and treatment plans as well as a follow-up questionnaire to investigate changes in symptoms after 4 wk of treatment.
RESULTS: Three thousand five hundred sixty-three patients from 42 centers across 24 cities in China were included. Epigastric pain (68.0%), abdominal distension (62.6%), and postprandial fullness (47.5%) were the most common presenting symptoms. Gastritis was classified as chronic non-atrophic in 69.9% of patients. Among those with erosive lesions, 72.1% of patients had lesions in the antrum, 51.0% had multiple lesions, and 67.3% had superficial flat lesions. In patients with epigastric pain, the combination of a mucosal protective agent (MPA) and proton pump inhibitor was more effective. For those with postprandial fullness, acid regurgitation, early satiety, or nausea, a MPA appeared more promising.
CONCLUSION: CEG is a multifactorial disease which is common in Asian patients and has non-specific symptoms. Gastroscopy may play a major role in its detection and diagnosis. Treatment should be individualized based on symptom profile.
The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
Apparatus and methods for fulfillment of patient prescription orders by adapting a standard or stock container pre-filled with medication or the like for use as a patient-specific container through precise application of patient-specific information to the pre-filled container. Precise placement of the patient-specific information to the pre-filled container enables pharmacy management to fully utilize valuable information provided with the pre-filled container, thereby improving the quality of service to the patient while making the process of prescription order fulfillment more efficient. In general, preferred embodiments comprise control apparatus and information-application apparatus. In embodiments, the information-application apparatus is adapted to place a patient-specific label on the container. Preferred forms of the information-application apparatus include a label printer and a positioner. The preferred printer applies patient-specific information on a label. The preferred positioner orients the pre-filled container to receive the label from the printer such that information provided with the container is available for use.
Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
The therapeutic efficacy of bone marrow mesenchymal stem cells (BMSCs) in myocardial infarction (MI) is hindered by poor cell survival. This study explored the role of N6-methyladenosine (m6A) regulation, specifically YTHDC1, in improving BMSC transplantation for MI. By screening m6A-related regulators in hypoxia and serum deprivation (HSD)-induced BMSC apoptosis, YTHDC1 was found to be downregulated. Overexpression of Ythdc1 in BMSCs reduced apoptosis markers, reactive oxygen species (ROS) release, and improved cell survival under HSD conditions. Conversely, Ythdc1 knockdown enhanced apoptosis. In rat MI models, transplantation of Ythdc1-overexpressing BMSCs improved cardiac function and reduced myocardial fibrosis. Mechanistically, YTHDC1 interacts with nuclear factor kappa B (NF-κB) inhibitor-alpha mRNA, suggesting its involvement in BMSC survival pathways. This study identifies YTHDC1 as a potential target to enhance BMSC efficacy in MI therapy.